# Valo Health

Valo Health is an Asset Manager based in Boston, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** Boston, MA, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** valohealth.com
- **LinkedIn:** https://www.linkedin.com/company/valo-health

## Regulatory record

- **Reports private funds:** No

## About

Valo Health is a pharmaceutical company founded in 2019 in Lexington, Massachusetts. It was previously known as Integral Health. The company offers the Opal Computational Platform, which integrates machine learning, tissue biology, and patient data for drug discovery and development.

## Sectors

- AI/ML
- Digital Health
- Biotech
- Pharmaceuticals
- Healthcare Services
- Drug Discovery

## Offices

- New York, United States

## People

- David Berry — Founder
- James Lis — President and COO
- Markus Covert — Chief Scientific Officer

## Questions

### Who controls Valo Health's investment decisions?

David Berry, CEO and founder, retains majority control. The board includes representatives from Flagship Pioneering and Google Ventures. Major strategic decisions, including partnerships and capital raises, require board approval.

### Is Valo Health a biotech or an AI platform company?

Valo is a biotech company wrapped in an AI platform — it develops its own therapeutic candidates internally but uses its Opus computational platform as the primary discovery tool. It does not operate a traditional wet-lab, instead relying on external contract research organizations for experimental validation.

### How does Valo Health differentiate from other AI drug discovery firms?

Valo's approach centers on using 'human data' — clinical records, genomic datasets, and real-world evidence — to train its models, rather than purely public molecular databases. This integration of population-scale data with proprietary ML models is a distinguishing structural choice.

### Has Valo Health taken any drug candidates into clinical trials?

As of early 2024, Valo had not yet advanced a wholly-owned candidate into Phase 1 trials. Its most advanced program, a collaboration with Bristol Myers Squibb for oncology targets, was in preclinical stages. The firm's near-term revenue comes from partnership payments and milestone fees, not product sales.

### What is Valo Health's relationship with Flagship Pioneering?

Valo was founded by a former Flagship partner and is partially backed by Flagship's early-stage venture funds, but it operates as an independent company with its own board and financing. It is not a Flagship portfolio company in the traditional sense, though Flagship retains a board seat.

### Which therapeutic areas does Valo Health prioritize?

Valo's pipeline focuses on oncology (particularly immuno-oncology), cardiovascular disease, and neurodegenerative conditions (Alzheimer's, tauopathies). The firm has also explored metabolic diseases through the Novo Nordisk collaboration. Respiratory and rare diseases are secondary areas of interest.

## Related profiles

- [Applied Composites Engineering](https://altss.com/profile/applied-composites-engineering)
- [Prologis](https://altss.com/profile/prologis)

---

Last updated: 2026-06-28T01:59:45.408Z

Canonical page: https://altss.com/profile/valo-health

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology